Evidence map›Paper›PMID 26251001›Full record

ArticleThe American journal of cardiology2015

Relation of Combined Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis in Adults With Type 1 Diabetes Mellitus.

Petter Bjornstad, Robert H Eckel, Laura Pyle, Marian Rewers, David M Maahs, Janet K Snell-Bergeon

Abstract read
In one paragraph

Article in The American journal of cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Type 1 diabetes and cardiovascular medicine.Cardiovascular diabetology. Endocrinology reports · 2026
    Review
  4. Article
  5. Cardiovascular Risk in Type 1 Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
    Review
  6. Observational
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Petter BjornstadDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado; Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado. Electronic address: petter.m.bjornstad@ucdenver.edu.
Robert H EckelDepartment of Endocrinology, University of Colorado Denver, Aurora, Colorado.
Laura PyleDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.
Marian RewersDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado; Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado.
David M MaahsDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado; Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado.
Janet K Snell-BergeonDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado; Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado.
University of Colorado Denver · US

Funding

ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI KOSMISKI, LISA A. · 1985 to 2008
$52.6M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
UCHSC DIABETES ENDOCRINOLOGY RESEARCH CENTERP30DK057516 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HUTTON, JOHN C · 2000 to 2010
$14.0M
SUBCLINICAL HEART DISEASE IN INSULIN-DEPENDENT DIABETESR01HL061753 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 1999 to 2007
$5.2M
Complications and Comorbidities of Type 1 DiabetesR01HL113029 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SNELL-BERGEON, JANET KATHLEEN · 2013 to 2016
$2.9M
Determinants of Accelerated CVD in Type 1 DiabetesR01HL079611 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 2004 to 2007
$2.3M
NCATS NIH HHS UL1 TR001082NCRR NIH HHS M01 RR000051NCRR NIH HHS M01-RR00051NHLBI NIH HHS HL113029NHLBI NIH HHS HL79611NHLBI NIH HHS R01 HL061753NHLBI NIH HHS R01 HL079611NHLBI NIH HHS R01 HL113029NHLBI NIH HHS R01 HL61753NIDDK NIH HHS P30 DK057516NIDDK NIH HHS P30 DK57516
6 · The paper itself

Abstract

Apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (non-HDL-C) are cardiovascular disease risk markers, although data in adults with type 1 diabetes mellitus (DM) are limited. We hypothesized that elevated apoB and non-HDL-C would be associated with greater odds of coronary artery calcification progression (CACp), a measure of coronary atherosclerosis, than either category alone in adults with type 1 DM. We grouped subjects with type 1 DM (n = 652) into 4 groups: elevated apoB (≥90 mg/dl) and elevated non-HDL-C (≥130 mg/dl), elevated non-HDL-C alone, elevated apoB alone, and normal apoB and non-HDL-C. We used logistic regression to examine the associations between the groups and CACp for a period of 6 years. We performed sensitivity analyses with elevated apoB and non-HDL-C redefined as at or more than the cohort means (91.4 and 119.0 mg/dl, respectively). Subjects with elevated apoB and non-HDL-C had greater odds of CACp compared with those with normal apoB and non-HDL-C (odds ratio 1.90, 95% confidence interval 1.15 to 3.15) and compared with subjects with elevated apoB alone (odds ratio 2.86, 95% confidence interval 1.43 to 5.74) adjusting for age, gender, duration, hemoglobin A1c, and statins. Similar results were obtained with elevated apoB and non-HDL-C defined as at or more than the cohort means. In conclusion, elevated apoB and non-HDL-C carry a greater risk of atherosclerosis than elevated apoB in the absence of elevated non-HDL-C in adults with type 1 DM. These data suggest that apoB and non-HDL-C should be viewed as complementary rather than competitive indexes of cardiovascular disease risk in type 1 DM.

Indexed as

AdultApolipoproteins BAtherosclerosisBiomarkersBody Mass IndexCalcinosisCholesterol, HDLColoradoCoronary Artery DiseaseDiabetes Mellitus, Type 1FemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedApolipoproteins BBiomarkersCholesterol, HDL

Identifiers

PMID26251001
PMCPMC4567927
OpenAlexW1906446064

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.